Skba Capital Management LLC Sells 100 Shares of Merck & Co., Inc. (NYSE:MRK)

Skba Capital Management LLC cut its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 0.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 165,335 shares of the company’s stock after selling 100 shares during the period. Merck & Co., Inc. comprises about 3.1% of Skba Capital Management LLC’s holdings, making the stock its 3rd largest position. Skba Capital Management LLC’s holdings in Merck & Co., Inc. were worth $17,021,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in MRK. Peddock Capital Advisors LLC raised its stake in Merck & Co., Inc. by 8.3% in the 2nd quarter. Peddock Capital Advisors LLC now owns 16,794 shares of the company’s stock valued at $1,938,000 after purchasing an additional 1,286 shares during the last quarter. Calamos Wealth Management LLC increased its stake in shares of Merck & Co., Inc. by 1.5% during the 2nd quarter. Calamos Wealth Management LLC now owns 19,388 shares of the company’s stock valued at $2,237,000 after acquiring an additional 286 shares during the last quarter. Richard P Slaughter Associates Inc increased its stake in shares of Merck & Co., Inc. by 8.8% during the 3rd quarter. Richard P Slaughter Associates Inc now owns 13,532 shares of the company’s stock valued at $1,393,000 after acquiring an additional 1,091 shares during the last quarter. Wealthspire Advisors LLC increased its stake in shares of Merck & Co., Inc. by 37.0% during the 3rd quarter. Wealthspire Advisors LLC now owns 57,526 shares of the company’s stock valued at $5,922,000 after acquiring an additional 15,529 shares during the last quarter. Finally, TruWealth Advisors LLC increased its stake in shares of Merck & Co., Inc. by 3.4% during the 2nd quarter. TruWealth Advisors LLC now owns 8,274 shares of the company’s stock valued at $955,000 after acquiring an additional 272 shares during the last quarter. 74.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is currently owned by company insiders.

Merck & Co., Inc. Stock Down 0.5 %

Shares of Merck & Co., Inc. stock traded down $0.67 on Monday, hitting $124.78. 1,028,356 shares of the company’s stock traded hands, compared to its average volume of 7,913,307. The stock has a market cap of $316.20 billion, a P/E ratio of 896.07, a PEG ratio of 1.62 and a beta of 0.38. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.82. The firm’s 50-day moving average is $114.58 and its 200 day moving average is $108.49. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $128.06.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.07% and a net margin of 0.61%. The firm had revenue of $14.63 billion for the quarter, compared to analysts’ expectations of $14.49 billion. During the same period last year, the business posted $1.62 earnings per share. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Equities analysts anticipate that Merck & Co., Inc. will post 8.6 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 2.47%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 2,200.00%.

Analysts Set New Price Targets

A number of research firms have recently commented on MRK. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, February 5th. TD Cowen raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Merck & Co., Inc. in a research note on Thursday, November 9th. They set a “buy” rating and a $115.00 price objective for the company. Wells Fargo & Company increased their target price on shares of Merck & Co., Inc. from $125.00 to $130.00 and gave the stock an “equal weight” rating in a research report on Friday, February 2nd. Finally, Truist Financial increased their target price on shares of Merck & Co., Inc. from $122.00 to $139.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.68.

Check Out Our Latest Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.